

Sangamo BioSciences, Inc.
Point Richmond Tech Center
501 Canal Blvd., Suite A100
Richmond, CA 94804
510-970-6000 • 510-236-8951(Fax)

SANGAMO BIOSCIENCES APPOINTS JON JACOBY TO ITS BOARD

Point Richmond, California – April 28, 2000 – Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the appointment of Jon E. M. Jacoby to its board of directors. Mr. Jacoby is currently a director and an executive vice president of Stephens Group, Inc., which invested in Sangamo prior to its initial public offering. He is also a senior executive vice president of Stephens Inc., an affiliate of Stephens Group, Inc., where he has been employed since 1963. Stephens Inc., headquartered in Little Rock, Arkansas, is an investment bank.

“Jon’s investment experience and strategic perspective will be helpful to Sangamo as we grow our base business and implement our multi-tiered business model,” said Edward Lanphier, Sangamo’s president and chief executive officer. “His experience analyzing investments across a wide range of industries will complement the scientific and operational competencies of our existing board.”

Mr. Jacoby joins Sangamo board members: Herbert W. Boyer, Ph.D., the co-inventor of recombinant DNA technology and founder of Genentech, Inc.; William G. Gerber, M.D., chief executive officer of Epoch Pharmaceuticals, Inc.; Edward Lanphier, president and chief executive officer of Sangamo BioSciences; John W. Larson, former chief executive officer of Brobeck, Phleger & Harrison LLP; William J. Rutter, Ph.D., co-founder of Chiron Corporation; and Michael C. Wood, president and founder of Knowledge Kids Enterprises, Inc., an educational company.

Mr. Jacoby also serves on the board of directors of Delta and Pine Land Company, Beverly Enterprises, Inc., and Power-One, Inc., as well as on the boards of several privately held companies. He received his B.S. degree from the University of Notre Dame and his M.B.A. from Harvard Business School.

About Sangamo

Sangamo is focused on the research and development of novel transcription factors for the regulation of genes. Sangamo’s Universal Gene Recognition technology enables the engineering of transcription factors known as zinc finger DNA binding proteins, or ZFPs. By engineering ZFPs so that they can recognize a specific gene, Sangamo has created ZFP transcription factors that can control gene expression and, consequently, cell function. The company intends to establish Universal Gene Recognition as a widely used technology for commercial applications in pharmaceutical discovery, therapeutics for the treatment of human diseases, clinical diagnostics, and agricultural and industrial biotechnology.

This press release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbors created by those sections. Those forward-looking statements include statements related to the ability of Sangamo BioSciences, Inc. to continue to meet marketing, technology, and customer demands as it relates to its products within the gene regulation market. Actual results may differ materially due to

Sangamo BioSciences, Inc.
Point Richmond Tech Center
501 Canal Blvd., Suite A100
Richmond, CA 94804
510-970-6000 • 510-236-8951(Fax)

a number of factors, including numerous technological, operational and financial challenges associated with the regulation of genes. The matters discussed in this press release also involve risks and uncertainties concerning Sangamo's products and services described in Sangamo's filing on Form S-1 with the SEC. In particular, see the risk factors described in the company's Registration Statement on Form S-1. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

Contacts: Edward Lanphier
Sangamo BioSciences, Inc.
510-970-6000, x207
lanphier@sangamo.com

Julie Wood
Sangamo BioSciences, Inc.
510-970-6000, x256
jwood@sangamo.com

###